This indicates the effectiveness of both administration routes in aiding weight loss
One commonly reported side effect is fatigue
An open-label RCT in n = 44 patients with obesity and subclinical binge-eating found a greater reduction in binge-eating at 12 weeks in liraglutide versus control (diet and exercise) groups [20]
The guidelines are expected to be published soon, following a public consultation held in September
However, Eli Lilly, the maker of Zepbound, received FDA approval on April 1, 2026 for Foundayo (orforglipron), a once-daily oral GLP-1 weight loss pill that can be taken any time of day, with or without food
Instead of broadly sedating you, they aim to fine-tune the signaling pathways that shape focus, stress resilience, and emotional balance